Drugs for Lynch Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 85)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Pancrelipase |
Approved, Investigational |
Phase 3 |
|
53608-75-6 |
8519 |
Synonyms:
1,4-ALPHA-D- GLUCAN GLUCANOHYDROLASE
ACCELERASE
COTAZYM
COTAZYM-S
CREON
Endothall
Endothall dipotassium salt
Endothall disodium salt
Endothall disodium salt, (endo,endo)-isomer
Endothall, diammonium salt
ENTOLASE
ILOZYME
KU-ZYME HP
LIPANCREATIN
lipase
|
PA
Pancrealipase
PANCREASE
PANCREATIC ALPHA-AMYLASE PRECURSOR
Pancreatic extract pancrelipase
Pancreatic protease
Pancreatin
Pancreatinum
PANCRELIPASE
Pancrelipase (amylase
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)
protease)
VIOKASE
ZYMASE
|
|
2 |
|
Atezolizumab |
Approved, Investigational |
Phase 3 |
|
1380723-44-3 |
|
Synonyms:
ANTI-PDL1
ANTI-PD-L1
ATEZOLIZUMAB
MPDL3280A
|
MPDL-3280A
RG-7446
TECENTRIQ
|
|
3 |
|
Levoleucovorin |
Approved, Experimental, Investigational |
Phase 3 |
|
68538-85-2, 58-05-9, 73951-54-9 |
149436 6006 |
Synonyms:
(5-formyl-5,6,7,8-tetrahydropteroyl)glutamate
(6R)-Leucovorin
(6R,2'S)-Folinic acid
(6R,S)-5-Formyltetrahydrofolate
(6S)-5-Formyl-5,6,7,8-tetrahydrofolate
(6S)-5-FORMYL-5,6,7,8-TETRAHYDROFOLIC ACID
(6S)-5-Formyltetrahydrofolate
(6S)-5-FORMYLTETRAHYDROFOLIC ACID
(6S)-Folinate
(6S)-FOLINIC ACID
(6S)-LEUCOVORIN
(S)-LEUCOVORIN
[6R]-5-formyl-5,6,7,8-tetrahydrofolate
10-Formyl-7,8-dihydrofolate
10-Formyl-7,8-dihydrofolic acid
5 Formyltetrahydrofolate
5 Formyltetrahydropteroylglutamate
5-Formlyl-5,6,7,8-tetrahydrofolate,calcium salt
5-Formyl-(6S)-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydrofolate
5-Formyl-5,6,7,8-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic acid
5-Formyltetrahydrofolate
5-Formyltetrahydrofolic acid
5-Formyltetrahydropteroylglutamate
5-Formyltetrahydropteroylglutamic acid
5-formylTHF
6 S Leucovorin
6R-Leucovorin
6S Leucovorin
6S-Leucovorin
6-S-Leucovorin
Acid, folinic
Acide folinique
Acido folinico
ácido levofolínico
Calcium citrovorum factor
Calcium folinate
Calcium leucovorin
CF
Citrovorum factor
Dextrofolinic acid
Factor, citrovorum
Folinate
Folinate, calcium
Folinic acid
Folinic acid calcium salt
Folinic acid calcium salt USP27
Folinic acid SF
Folinic acid-SF
FUSILEV
KHAPZORY
|
Kunyrin
L(-)-5-Formyl-5,6,7,8-tetrahydrofolate
L(-)-5-Formyl-5,6,7,8-tetrahydrofolic acid
Leucal
Leucoverin
Leucovorin
Leucovorin calcium
Leucovorin folinic acid
Leucovorin, (D)-isomer
Leucovorin, (DL)-isomer
Leucovorin, (R)-isomer
Leucovorin, (S)-isomer
Leucovorin, calcium
Leucovorin, calcium (1:1) salt
Leucovorin, calcium (1:1) salt, (DL)-isomer
Leucovorin, calcium (1:1) salt, (S)-isomer
Leucovorin, calcium (1:1) salt, pentahydrate
Leucovorin, monopotassium salt, (S)-isomer
Leucovorin, monosodium salt
Leucovorin, monosodium salt, (S)-isomer
Leucovorinum
Leukovorin
Leukovorum
Levo leucovorin
LEVOFOLENE
Levofolinate
LEVOFOLINIC ACID
Levoleucovorin
Levo-leucovorin
L-Folinate
L-FOLINIC ACID
LFP-754
L-Leucovorin
L-N-[P-[[(2-amino-5-Formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl]amino]benzoyl]-glutamic acid
Monosodium salt leucovorin
N(5)-Formyltetrahydrofolate
N-(5-formyl-5,6,7,8-tetrahydropteroyl)-L-glutamic acid
N-[4-({[(6S)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamate
N-[4-({[(6S)-2-AMINO-5-FORMYL-4-OXO-1,4,5,6,7,8-HEXAHYDROPTERIDIN-6-YL]METHYL}AMINO)BENZOYL]-L-GLUTAMIC ACID
N-{[4-({[(6R)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)phenyl]carbonyl}-L-glutamic acid
N5-Formyl-5,6,7,8-tetrahydrofolate
N5-Formyl-5,6,7,8-tetrahydrofolic acid
N5-Formyltetrahydrofolate
N5-Formyltetrahydrofolic acid
N5-Formyl-THF
Pteroyl-D-glutamate
Rescuvolin
S Leucovorin
S-Leucovorin
Welcovorin
Wellcovorin
|
|
4 |
|
Bevacizumab |
Approved, Investigational |
Phase 3 |
|
216974-75-3 |
135329020 |
Synonyms:
12-IGG1
ANTIVEGF
Anti-VEGF Humanized Monoclonal Antibody
Anti-VEGF monoclonal antibody
AVA-1
AVASTIN
Bevacizumab
BEVACIZUMAB BETA
bevacizumab-awwb
|
BI 695502
BS-503A
FKB-238
HLX04
HLX-04
R-435
RG-435
RHUMAB-
rhuMAb-VEGF
|
|
5 |
|
Fluorouracil |
Approved |
Phase 3 |
|
51-21-8 |
3385 |
Synonyms:
5 Fluorouracil
5 Fluorouracil biosyn
5 FU
5 FU lederle
5 FU medac
5 HU hexal
5.F.U.
5-Fluoracil
5-Fluoropyrimidine-2,4-dione
5-Fluorouracil
5-Fluorouracil-biosyn
5-Fluracil
5FU
5-FU
5-FU lederle
5-FU medac
5-HU hexal
ACCUSITE
ACTIKERALL
Adrucil
Allergan brand OF fluorouracil
Arumel
Biosyn brand OF fluorouracil
Carac
Carzonal
CSP Brand OF fluorouracil
Dakota brand OF fluorouracil
Dakota, fluorouracile
Dermatech brand OF fluorouracil
Dermik brand OF fluorouracil
Effluderm
Efudex
Efudix
Efurix
Ferrer brand OF fluorouracil
Fluoro Uracil
Fluoro uracile icn
Fluoroblastin
Fluoroplex
Fluorouracil
Fluorouracil gry
Fluorouracil mononitrate
Fluorouracil monopotassium salt
Fluorouracil monosodium salt
Fluorouracil potassium salt
FLUORO-URACIL ROCHE
Fluorouracil teva brand
|
Fluorouracile dakota
Fluoro-uracile icn
Fluorouracil-gry
Fluorouracilo
Fluorouracilo ferrer far
Fluorouracilum
Fluoruracil
Fluouracil
Fluracedyl
FLURACIL
Fluracilum
Fluri
Fluril
Fluro Uracil
Flurodex
Flurouracil
Ftoruracil
FU
Gry brand OF fluorouracil
Haemato brand OF fluorouracil
Haemato fu
Haemato-fu
Hexal brand OF fluorouracil
ICN brand OF fluorouracil
Kecimeton
Medac brand OF fluorouracil
Neocorp brand OF fluorouracil
Neofluor
NSC-19893
Onkofluor
Onkoworks brand OF fluorouracil
Pharmachemie brand OF fluorouracil monosodium salt
Phthoruracil
Phtoruracil
Queroplex
Ribofluor
Ribosepharm brand OF fluorouracil
Riemser brand OF fluorouracil
RO-29757
RO-2-9757
Roche brand OF fluorouracil
Teva brand OF fluorouracil
Timazin
TOLAK
Ulup
URF
|
|
6 |
|
Oxaliplatin |
Approved, Investigational |
Phase 3 |
|
61825-94-3 |
43805 11947679 6857599 |
Synonyms:
ACT 078
ACT-078
DACPLAT
Diaminocyclohexane Oxalatoplatinum
Eloxatin
Eloxatine
Elplat
Foloxatine
JM-83
L-OHP
L-OHP CPD
MBP-426 (LIPOSOMAL OXALIPLATIN)
NSC-266046
Oxalatoplatin
|
Oxalatoplatinum
Oxaliplatin
Oxaliplatin [Usan:Inn:Ban]
oxaliplatine
oxaliplatino
Oxaliplatino [Spanish]
oxaliplatinum
Oxaliplatinum [Latin]
Oxaloplatine [French]
Oxaloplatino [Spanish]
RP-54780
SR-96669
Transplatin
|
|
7 |
|
Acetylsalicylic acid |
Approved, Vet_approved |
Phase 3 |
|
50-78-2 |
2244 |
Synonyms:
2-(ACETYLOXY)BENZOATE
2-(ACETYLOXY)benzoIC ACID
2-Acetoxybenzenecarboxylate
2-ACETOXYBENZENECARBOXYLIC ACID
2-ACETOXYBENZOATE
2-ACETOXYBENZOIC ACID
2-CARBOXYPHENYL ACETATE
8-HOUR BAYER
A.S.A.
A.S.A. Empirin
ACARD
ACENTERINE
Acesal
Acetal
ACETARD
ACETICYL
Acetilsalicilico
Acetilum acidulatum
Acetisal
ACETOL
ACETONYL
ACETOPHEN
Acetophen®|acetylsalicylic acid|Aspirin®
ACETOSAL
ACETOSALIC ACID
ACETOSALIN
Acetoxybenzoic acid
ACETYLIN
Acetylsal
ACETYLSALIC ACID
ACETYLSALICYLATE
ACETYLSALICYLIC ACID
Acetylsalicylsaeure
Acetylsalicylsaure
ACETYLSALICYLSÄURE
ACETYONYL
ACETYSAL
ACETYSALICYLIC ACID
Acid, acetylsalicylic
Acide 2-(acetyloxy)benzoique
ACIDE 2-(ACÉTYLOXY)BENZOÏQUE
Acide acetylsalicylique
ACIDE ACÉTYLSALICYLIQUE
Acido acetilsalicilico
ÁCIDO ACETILSALICÍLICO
Acido O-acetil-benzoico
ACIDUM ACETYLSALICYLICUM
Acimetten
Acisal
ACYLPYRIN
Adiro
ALKA RAPID
Aloxiprimum
ANADIN ALL NIGHT
ANGETTES 75
ASA
Asagran
ASATARD
Ascoden-30
Aspalon
Aspec
ASPERGUM
ASPIRDROPS
ASPIRIN
Aspirina
Aspirine
Aspro
ASPRO CLR
Asteric
Azetylsalizylsaeure
AZETYLSALIZYLSÄURE
BAY1019036
BAYER EXTRA STRENGTH
Bayer Extra Strength Aspirin For Migraine Pain
BENASPIR
Bialpirina
BIALPIRINIA
Bi-prin
BUFFERIN
CAPRIN
CARDIOASPIRINA
Cemirit
Claradin
Clariprin
Colfarit
Contrheuma retard
Coricidin
Crystar
DANAMEP
Decaten
Delgesic
Dispril
DISPRIN CV
|
DISPRIN DIRECT
Dolean pH 8
Duramax
DURLAZA
EASPRIN
ECM
ECOLEN
ECOTRIN
EMPIRIN
ENDOSPRIN
ENDYDOL
ENPRIN
Entericin
Enterophen
Enterosarein
Enterosarine
Entrophen
EQUI-PRIN
Extren
GENCARDIA
Globentyl
Globoid
Helicon
Idragin
Kyselina 2-acetoxybenzoova
Kyselina acetylsalicylova
LEVIUS
Magnecyl
MAX STRGH ASPRO CLR
MEASURIN
Micristin
MICROPIRIN EC
Neuronika
Novid
NSC-27223
NSC-406186
Nu-seals
NU-SEALS 300
NU-SEALS 600
NU-SEALS 75
Nu-seals aspirin
NU-SEALS CARDIO 75
O-(ACETYLOXY)BENZOATE
O-(ACETYLOXY)BENZOIC ACID
O-accetylsalicylic acid
O-ACETOXYBENZOATE
O-ACETOXYBENZOIC ACID
O-Acetylsalicylate
O-ACETYLSALICYLIC ACID
O-CARBOXYPHENYL ACETATE
O-Carboxyphenyl acetic acid
PAYNOCIL
PERSISTIN
PHARMACIN
Pirseal
PLATET
PLATET 300
Polopirin
POLOPIRYNA
POSTMI 300
POSTMI 75
PREMASPIN
RHEUMINTABLETTEN
RHODINE
Rhonal
Salacetin
SALCETOGEN
SALETIN
Salicylate acetate
SALICYLIC ACID ACETATE
Salicylic acid acetic acid
Salicylic acid, acetate
SALOSPIR
Solfrin
SOLPRIN
SOLPRIN ACID
SOLPYRON
Solupsan
Spira-Dine
St. Joseph
St. Joseph Aspirin for Adults
Supac
TASPRIN
TEMPERAL
TOLDEX
TRIAMINICIN
Triple-sal
Vanquish
VAZALORE
Xaxa
Yasta
Zorprin
|
|
8 |
|
Levonorgestrel |
Approved, Investigational |
Phase 3 |
|
797-63-7 |
13109 |
Synonyms:
(-)-13-Ethyl-17-hydroxy-18,19-dinor-17alpha-pregn-4-en-20-yn-3-one
(-)-13-Ethyl-17-hydroxy-18,19-dinor-17a-pregn-4-en-20-yn-3-one
(-)-13-Ethyl-17-hydroxy-18,19-dinor-17α-pregn-4-en-20-yn-3-one
(+-)-Norgestrel
(8R,9S,10R,13S,14S,17R)-13-ETHYL-17-ETHYNYL-17-HYDROXY- 1,2,6,7,8,9,10,11,12,13,14,15,16, 17- TETRADECAHYDROCYCLOPENTA[A] PHENANTHREN-3-ONE
13-beta-Ethyl-17alpha-ethynyl-17beta-hydroxygon-4-en-3-one
13-b-Ethyl-17a-ethynyl-17b-hydroxygon-4-en-3-one
13-Ethyl-17-a-ethynyl-17-b-hydroxy-4-gonen-3-one
13-Ethyl-17-a-ethynylgon-4-en-17-b-ol-3-one
13-Ethyl-17-alpha-ethynyl-17-beta-hydroxy-4-gonen-3-one
13-Ethyl-17-alpha-ethynylgon-4-en-17-beta-ol-3-one
13-Ethyl-17-α-ethynyl-17-β-hydroxy-4-gonen-3-one
13-Ethyl-17-α-ethynylgon-4-en-17-β-ol-3-one
13-Β-ethyl-17α-ethynyl-17β-hydroxygon-4-en-3-one
17-a-Ethinyl-13-b-ethyl-17-b-hydroxy-4-estren-3-one
17a-Ethynyl-13b-ethyl-3-oxo-4-estren-17b-ol
17-a-Ethynyl-13-ethyl-19-nortestosterone
17a-Ethynyl-17-hydroxy-18-methylestr-4-en-3-one
17a-Ethynyl-18-homo-19-nortestosterone
17-alpha-Ethinyl-13-beta-ethyl-17-beta-hydroxy-4-estren-3-one
17alpha-Ethynyl-13beta-ethyl-3-oxo-4-estren-17beta-ol
17-alpha-Ethynyl-13-ethyl-19-nortestosterone
17alpha-Ethynyl-17-hydroxy-18-methylestr-4-en-3-one
17alpha-Ethynyl-18-homo-19-nortestosterone
17-Ethynyl-18-methyl-19-nortestosterone
17-Α-ethinyl-13-β-ethyl-17-β-hydroxy-4-estren-3-one
17-Α-ethynyl-13-ethyl-19-nortestosterone
17Α-ethynyl-13β-ethyl-3-oxo-4-estren-17β-ol
17Α-ethynyl-17-hydroxy-18-methylestr-4-en-3-one
17Α-ethynyl-18-homo-19-nortestosterone
18-Methyl-17-a-ethynyl-19-nortestosterone
18-Methyl-17-alpha-ethynyl-19-nortestosterone
18-Methyl-17-α-ethynyl-19-nortestosterone
18-Methylnorethisterone
Alcala brand OF levonorgestrel
ATHENTIA NEXT
Aventis pharma brand OF levonorgestrel
BAY86-5028
Berlex brand OF levonorgestrel
Capronor
Cerazet
D Norgestrel
D(-)-Norgestrel
D-Norgestrel
Duofem
EMERRES
EMERRES UNA
EZINELLE
FALLBACK SOLO
HER STYLE
Hexal brand OF levonorgestrel
HRA brand 1 OF levonorgestrel
HRA brand 2 OF levonorgestrel
|
ISTERANDA
Jadelle
JAYDESS
KYLEENA
L Norgestrel
Levonelle
LEVONELLE ONE STEP
LEVONELLE-2
Levonorgestrel
LÉVONORGESTREL
Lèvonorgestrel
Levonorgestrel alcala brand
Levonorgestrel berlex brand
Levonorgestrel hexal brand
Levonorgestrel paladin brand
Levonorgestrel wyeth brand
Levonorgestrelum
Levonova
LEVOSERT
LILETTA
L-Norgestrel
l-norgestrel|Norplant®
Microlut
Microluton
Microval
Mirena
Norgeston
NORGESTREL (-)-FORM
NorLevo
Norplant
Norplant 2
NORPLANT II
NORPLANT SYSTEM
Norplant2
Norplant-2
OPCICON ONE-STEP
Ovrette
Paladin brand OF levonorgestrel
Plan b
PLAN B ONE-STEP
Postinor
POSTINOR-2
Schering brand 1 OF levonorgestrel
Schering brand 2 OF levonorgestrel
Schering brand 3 OF levonorgestrel
SKYLA
UPOSTELLE
Vikela
Women's capital brand OF levonorgestrel
WY-3707
WY-5104
Wyeth brand OF levonorgestrel
|
|
9 |
|
Folic acid |
Approved, Nutraceutical, Vet_approved |
Phase 3 |
|
59-30-3 |
6037 |
Synonyms:
(2S)-2-[(4-{[(2-AMINO-4-OXO-1,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}PHENYL)FORMAMIDO]PENTANEDIOIC ACID
(2S)-2-[[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]PHENYL]-OXO-METHYL]AMINO]PENTANEDIOIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]BENZOYL]AMINO]GLUTARIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]BENZOYL]AMINO]PENTANEDIOIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]PHENYL]CARBONYLAMINO]PENTANEDIOIC ACID
[<sup>3</sup>H]-folic acid
Acide folique
ácido fólico
Acidum folicum
ACIFOLIC
Apo-Folic
B03BB01
b9, Vitamin
BIO SCIENCE
CYTOFOL
DOSFOLAT B ACTIV
FOLACID
FOLACIN
FOLATE
FOLBAL
FOLCIDIN
FOLDINE
FOLETTES
FOLIAMIN
FOLIC ACID
Folic acid, (D)-isomer
Folic acid, (DL)-isomer
Folic acid, calcium salt (1:1)
Folic acid, monopotassium salt
Folic acid, monosodium salt
Folic acid, potassium salt
Folic acid, sodium salt
FOLICARE
FOLICET
FOLIPAC
|
FOLSAEURE
FOLSAN
FOLSAURE
Folsäure
FOLSAV
FOLVITE
Folvron
INCAFOLIC
LEXPEC
LIVER LACTOBACILLUS CASEI FACTOR
MILLAFOL
N-(4-{[(2-AMINO-4-OXO-3,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}BENZOYL)-L-GLUTAMIC ACID
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamate
N-[(4-{[(2-AMINO-4-OXO-1,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}PHENYL)CARBONYL]-L-GLUTAMIC ACID
N-[4-[[(2-AMINO-3,4-DIHYDRO-4-OXO-6-PTERIDINYL)METHYL]AMINO]BENZOYL]-L-GLUTAMIC ACID
NATUR FLOW
N-Pteroyl-L-glutamate
N-PTEROYL-L-GLUTAMIC ACID
NSC-3073
PGA
PRECONCEIVE
PTEGLU
PTEROYLGLUTAMATE
PTEROYLGLUTAMIC ACID
PTEROYL-L-GLUTAMATE
PTEROYL-L-GLUTAMIC ACID
PTEROYL-L-MONOGLUTAMATE
PTEROYL-L-MONOGLUTAMIC ACID
PTEROYLMONOGLUTAMIC ACID
ROCHE
Vitamin B9
VITAMIN BC
VITAMIN BE
VITAMIN M
|
|
10 |
|
Immunoglobulins |
|
Phase 3 |
|
|
|
11 |
|
Antibodies |
|
Phase 3 |
|
|
|
12 |
|
Acetylsalicylic acid lysinate |
|
Phase 3 |
|
|
|
13 |
|
Hormone Antagonists |
|
Phase 3 |
|
|
|
14 |
|
Pancreatin |
|
Phase 3 |
|
|
|
15 |
|
Gastrointestinal Agents |
|
Phase 3 |
|
|
|
16 |
|
Secretin |
|
Phase 3 |
|
|
71306891 |
Synonyms:
SECRETIN
SECRETIN-FERRING
|
|
|
17 |
|
Antibodies, Monoclonal |
|
Phase 3 |
|
|
|
18 |
|
Antimetabolites |
|
Phase 3 |
|
|
|
19 |
|
Immunologic Factors |
|
Phase 3 |
|
|
|
20 |
|
Hormones |
|
Phase 3 |
|
|
|
21 |
|
Immunoglobulins, Intravenous |
|
Phase 3 |
|
|
|
22 |
|
Vitamins |
|
Phase 3 |
|
|
|
23 |
|
Folate |
|
Phase 3 |
|
|
|
24 |
|
Vitamin B9 |
|
Phase 3 |
|
|
|
25 |
|
Trace Elements |
|
Phase 3 |
|
|
|
26 |
|
Immunoglobulin G |
|
Phase 3 |
|
|
|
27 |
|
Angiogenesis Inhibitors |
|
Phase 3 |
|
|
|
28 |
|
Vitamin B Complex |
|
Phase 3 |
|
|
|
29 |
|
Antidotes |
|
Phase 3 |
|
|
|
30 |
|
Calcium, Dietary |
|
Phase 3 |
|
|
|
31 |
|
Immunosuppressive Agents |
|
Phase 3 |
|
|
|
32 |
|
Hematinics |
|
Phase 3 |
|
|
|
33 |
|
Micronutrients |
|
Phase 3 |
|
|
|
34 |
|
Protective Agents |
|
Phase 3 |
|
|
|
35 |
|
Endothelial Growth Factors |
|
Phase 3 |
|
|
|
36 |
|
Mitogens |
|
Phase 3 |
|
|
|
37 |
|
Analgesics |
|
Phase 3 |
|
|
|
38 |
|
Antirheumatic Agents |
|
Phase 3 |
|
|
|
39 |
|
Fibrinolytic Agents |
|
Phase 3 |
|
|
|
40 |
|
Antipyretics |
|
Phase 3 |
|
|
|
41 |
|
Cyclooxygenase Inhibitors |
|
Phase 3 |
|
|
|
42 |
|
Platelet Aggregation Inhibitors |
|
Phase 3 |
|
|
|
43 |
|
Anti-Inflammatory Agents, Non-Steroidal |
|
Phase 3 |
|
|
|
44 |
|
Analgesics, Non-Narcotic |
|
Phase 3 |
|
|
|
45 |
|
Anti-Inflammatory Agents |
|
Phase 3 |
|
|
|
46 |
|
Cola |
|
Phase 3 |
|
|
|
47 |
|
Contraceptives, Oral |
|
Phase 3 |
|
|
|
48 |
|
Contraceptive Agents |
|
Phase 3 |
|
|
|
49 |
|
Serine |
Investigational, Nutraceutical |
Phase 3 |
|
56-45-1 |
5951 |
Synonyms:
(-)-Serine
(2S)-2-Amino-3-hydroxypropanoate
(2S)-2-Amino-3-hydroxypropanoic acid
(3R,3'r,6S)-4,5-DIDEHYDRO-5,6-dihydro-b,b-carotene-3,3'-diol
(3R,3'r,6S)-4,5-DIDEHYDRO-5,6-dihydro-BETA,BETA-carotene-3,3'-diol
(3R,3'r,6S)-4,5-DIDEHYDRO-5,6-dihydro-β,β-carotene-3,3'-diol
(S)-(-)-Serine
(S)-2-Amino-3-hydroxypropanoate
(S)-2-Amino-3-hydroxy-propanoate
(S)-2-Amino-3-hydroxypropanoic acid
(S)-2-Amino-3-hydroxy-propanoic acid
(S)-a-Amino-b-hydroxypropionate
(S)-a-Amino-b-hydroxypropionic acid
(S)-alpha-Amino-beta-hydroxypropionate
(S)-alpha-Amino-beta-hydroxypropionic acid
(S)-b-Amino-3-hydroxypropionate
(S)-b-Amino-3-hydroxypropionic acid
(S)-beta-Amino-3-hydroxypropionate
(S)-beta-Amino-3-hydroxypropionic acid
(S)-Serine
(S)-Α-amino-β-hydroxypropionate
(S)-Α-amino-β-hydroxypropionic acid
2-Amino-3-hydroxypropanoate
2-Amino-3-hydroxypropanoic acid
3-Hydroxy-L-alanine
|
alpha-Amino-beta-hydroxypropionic acid
beta-Hydroxyalanine
beta-Hydroxy-L-alanine
b-Hydroxyalanine
b-Hydroxy-L-alanine
Bo-xan
e 161b
L Serine
L-(-)-Serine
L-2-Amino-3-hydroxypropionate
L-2-Amino-3-hydroxypropionic acid
L-3-Hydroxy-2-aminopropionate
L-3-Hydroxy-2-aminopropionic acid
L-3-Hydroxy-alanine
L-Ser
L-Serin
L-Serine
S
Ser
Serina
SERINE
Serinum
Xanthophyll
Î’-hydroxyalanine
Î’-hydroxy-L-alanine
|
|
50 |
|
Calcium |
Nutraceutical |
Phase 3 |
|
7440-70-2 |
271 |
Synonyms:
Ca
Ca(2+)
Ca2+
Calcio
CALCIUM
Calcium element
|
CALCIUM ion
Calcium(2+)
Calcium, doubly charged positive ion
Calcium, elemental
Elemental calcium
Kalzium
|
|
Interventional clinical trials:
(show top 50)
(show all 95)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
PD-1 Antibody for the Prevention of Adenomatous Polyps and Second Primary Tumors in Patients With Lynch Syndrome: An Open-label, Multicenter, Randomized Controlled Clinical Trial |
Recruiting |
NCT04711434 |
Phase 3 |
PD-1 Antibody |
2 |
Assessment of the Effect of a Daily Chemoprevention by Low-dose Aspirin of New or Recurrent Colorectal Adenomas in Patients With Lynch Syndrome |
Recruiting |
NCT02813824 |
Phase 3 |
Acetylsalicylic acid lysinate 300 mg;Placebo (for Aspirin 300);Acetylsalicylic acid lysinate 100 mg;Placebo 100 (for Aspirin 100) |
3 |
The Cancer of the Pancreas Screening-5 CAPS5)Study |
Recruiting |
NCT02000089 |
Phase 3 |
Secretin |
4 |
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair |
Recruiting |
NCT02912559 |
Phase 3 |
Atezolizumab;Fluorouracil;Leucovorin Calcium;Oxaliplatin |
5 |
A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin Versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients With Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers |
Active, not recruiting |
NCT00217737 |
Phase 3 |
Fluorouracil;Leucovorin Calcium;Oxaliplatin |
6 |
A Randomised Double Blind Dose Non-inferiority Trial of a Daily Dose of 600mg Versus 300mg Versus 100mg of Enteric Coated Aspirin as a Cancer Preventive in Carriers of a Germline Pathological Mismatch Repair Gene Defect, Lynch Syndrome |
Not yet recruiting |
NCT02497820 |
Phase 3 |
Aspirin |
7 |
Prevention of Endometrial Tumors (POET) |
Terminated |
NCT00566644 |
Phase 3 |
|
8 |
Early Detection of Pre-cancer Lesions in Adults With Hereditary Nonpolyposis Colorectal Cancer (HNPCC) Syndrome: Assessment of Coloscopy With Chromoscopy Benefit |
Completed |
NCT00224601 |
Phase 2 |
|
9 |
Modulation Of Putative Surrogate Endpoint Biomarkers In Endometrial Biopsies From Women With HNPCC |
Completed |
NCT00033358 |
Phase 2 |
medroxyprogesterone;ethinyl estradiol;norgestrel |
10 |
Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome |
Recruiting |
NCT04920149 |
Phase 2 |
Mesalamine;Placebo |
11 |
A Phase Ib/II Clinical Trial of Nous-209 for Recurrent Neoantigen Immunogenicity and Cancer Immune Interception in Lynch Syndrome |
Recruiting |
NCT05078866 |
Phase 1, Phase 2 |
|
12 |
PD-1 Antibody as a Sequential Therapy Following Preoperative Chemoradiotherapy for Locally Advanced pMMR/MSS Rectal Cancer: an Open, Multi-center, Phase II Clinical Trial |
Recruiting |
NCT04833387 |
Phase 2 |
PD-1 antibody |
13 |
Dendritic Cell Vaccination in Patients With Lynch Syndrome or Colorectal Cancer With MSI |
Active, not recruiting |
NCT01885702 |
Phase 1, Phase 2 |
|
14 |
Omega 3 Fatty Acids in Colorectal Cancer (CRC) Prevention in Patients With Lynch Syndrome (COLYNE) |
Active, not recruiting |
NCT03831698 |
Phase 2 |
Omega-3 fatty acid ethyl esters (2 gram) |
15 |
A Phase II Study of PD-1 Inhibition for the Prevention of Colon Adenomas in Patients With Lynch Syndrome and a History of Partial Colectomy |
Active, not recruiting |
NCT03631641 |
Phase 2 |
|
16 |
A Phase IIa Randomized, Double-Blinded Clinical Trial of Naproxen or Aspirin for Cancer Immune Interception in Lynch Syndrome |
Not yet recruiting |
NCT05411718 |
Phase 2 |
Naproxen;Aspirin |
17 |
A Phase IIB Clinical Trial of the Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury) Vaccine (TRI-AD5) and IL-15 Superagonist N-803 in Lynch Syndrome |
Not yet recruiting |
NCT05419011 |
Phase 2 |
Nogapendekin Alfa;Placebo Administration |
18 |
Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome - MesaCAPP |
Terminated |
NCT03070574 |
Phase 2 |
mesalamine 2400 MG (5-ASA);mesalamine 1200 MG |
19 |
A Phase Ib Biomarker Trial of Naproxen in Patients at Risk for DNA Mismatch Repair Deficient Colorectal Cancer |
Completed |
NCT02052908 |
Phase 1 |
Naproxen |
20 |
Phase I-II Multiple-Dose Safety and Efficacy Study of a Selective Inhibitor of Cyclooxygenase - 2 (SC-58635) in Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Patients and Carriers |
Completed |
NCT00001693 |
Phase 1 |
Celecoxib (SC-58635) |
21 |
A Safety and Preliminary Efficacy Trial of Pembrolizumab (MK-3475) in Children With Recurrent, Progressive or Refractory Diffuse Intrinsic Pontine Glioma (DIPG), Non-Brainstem High-Grade Gliomas (NB-HGG), Ependymoma, Medulloblastoma or Hypermutated Brain Tumors |
Recruiting |
NCT02359565 |
Phase 1 |
|
22 |
3CI Study: Childhood Cancer Combination Immunotherapy. Phase Ib and Expansion Study of Nivolumab Combination Immunotherapy in Children, Adolescent and Young Adult (CAYA) Patients With Relapsed/Refractory Hypermutant Cancers |
Withdrawn |
NCT04500548 |
Phase 1 |
|
23 |
Cohort Study of Universal Screening for Lynch Syndrome in Chinese Patients of Endometrial Cancer |
Unknown status |
NCT03291106 |
|
|
24 |
A Compare of Microsatellite Instability in Circulatory DNA and Tumor Tissue of Endometrial Cancer |
Unknown status |
NCT03744962 |
|
|
25 |
Personalized Prostate Cancer Screening Among Men With High Risk Genetic Predisposition- a Prospective Cohort Study |
Unknown status |
NCT02053805 |
|
|
26 |
Correlation Between Somatic Mismatch Repair Instability and Germline Mismatch Repair Instability, in Low Socioeconomic Background Population Diagnosed With Endometrial Endometrioid Adenocarcinoma |
Unknown status |
NCT04516083 |
|
|
27 |
Hereditary Nonpolyposis Colorectal Cancer in Taiwan-Related Genetic Study and Clinical Applications |
Unknown status |
NCT00262171 |
|
|
28 |
Cost Effectiveness of Two Different Implementation Procedures to Change Clinicians Practice Roles in the Detection of Hereditary Colorectal Cancer |
Unknown status |
NCT00141466 |
|
|
29 |
The Molecular Predisposition to Hereditary Nonpolyposis Colon Cancer (HNPCC) |
Unknown status |
NCT01447199 |
|
|
30 |
Implementation of Guidelines on Hereditary or Familial Colorectal Cancer Risk Calculation and Risk Communication |
Unknown status |
NCT00929097 |
|
|
31 |
Diagnosis of Lynch Syndrome Based on Next-generation Sequencing in Colorectal Cancer Patients Meeting Chinese Lynch Syndrome Criteria: An Open-label and Multi-center Study. |
Completed |
NCT03046849 |
|
|
32 |
Molecular Screening for Lynch Syndrome in Denmark |
Completed |
NCT01845753 |
|
|
33 |
Linked Color Imaging Versus High-definition White Light Endoscopy for the Detection of Polyps in Patients With Lynch Syndrome. An International, Multicenter, Parallel Randomized Controlled Trial. |
Completed |
NCT03344289 |
|
|
34 |
Diagnosis of Lynch Syndrome Based on the Colorectal Coreâ„¢ Platform in Colorectal Cancer Patients With the Loss of Staining by Immunohistochemistry (IHC) of Any of the Mismatch Repair (MMR) Proteins: An Open-label and Multi-center Study |
Completed |
NCT03047226 |
|
|
35 |
High Definition White-Light Colonoscopy Versus Chromoendoscopy for Surveillance of Lynch Syndrome. A Prospective, Multicenter and Randomized Study |
Completed |
NCT02951390 |
|
|
36 |
Ohio Colorectal Cancer Prevention Initiative: Universal Screening for Lynch Syndrome |
Completed |
NCT01850654 |
|
|
37 |
Cancer Survivorship in Lynch Syndrome: Impact on Patients and Families |
Completed |
NCT01126840 |
|
|
38 |
Predictive Factor Study of the Occurrence of Endometrial Cancer in Patients With Lynch Syndrome: Study Conducted in the Hauts-de-France |
Completed |
NCT04452266 |
|
|
39 |
Living in Lynch Syndrome Limbo: Exploring the Meaning of Uncertain Genetic Test Results |
Completed |
NCT01646112 |
|
|
40 |
Chromoendoscopy in Lynch Syndrome Patients |
Completed |
NCT00905710 |
|
|
41 |
Capsule Endoscopy in Lynch Syndrome for Small Intestinal Tumor Screening |
Completed |
NCT00898768 |
Early Phase 1 |
|
42 |
Molecular Screening for Lynch Syndrome in Southern Denmark |
Completed |
NCT01216930 |
|
|
43 |
Integrating Genetic Testing for Lynch Syndrome in a Managed Care Setting |
Completed |
NCT01582841 |
|
|
44 |
Identifying the Risk of Hereditary and Familial Colorectal Cancer in Colorectal Cancer Patients by Using an Online Risk Tool: An Evaluation Based on a Stepped Wedge Design |
Completed |
NCT02645084 |
|
|
45 |
Hereditary Colorectal and Associated Tumor Registry Study |
Completed |
NCT00633607 |
|
|
46 |
Comparison of Colonoscopy With Virtual Chromoendoscopy Using 3rd Generation NBI System to Chromoendoscopy With Indigo Carmine in Lynch Patients. |
Completed |
NCT02570516 |
|
|
47 |
Telemedicine vs. Face-to-Face Cancer Genetic Counseling in Rural Oncology Clinics |
Completed |
NCT00609505 |
|
|
48 |
High Definition Endoscopy Versus Virtual Chromoendoscopy In The Detection Of Colonic Polyps In HNPCC |
Completed |
NCT01823471 |
|
|
49 |
Preliminary Evaluation of Septin9 in Patients With Hereditary Colon Cancer Syndromes |
Completed |
NCT02198092 |
|
|
50 |
Psychosocial Aspects of Genetic Testing for HNPCC |
Completed |
NCT00341575 |
|
|
|